Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One RNAi-Related Patent

Premium
Title: Nanoparticle Delivery Vehicle
 
Number: 7,332,586
 
Filed: July 10, 2002
 
Lead Inventor: Stefan Franzen, North Carolina State University
 
The patent, its abstract states, claims “a nanoparticle delivery vehicle comprising a nanoparticle, an active agent, and a nuclear localization signal and methods of modulating gene expression and protein expression employing the nanoparticle delivery vehicle.”
 
This nanoparticle, the abstract adds, has “a diameter of about 30 nm or less” and contacts “a target cell … whereby an active agent is delivered to the nucleus of a target cell. Another representative method includes … a nanoparticle having a diameter greater than or equal to about 30 nm, an active agent, and a nuclear localization signal, [which contact] a target cell with the nanoparticle delivery vehicle, whereby an active agent is delivered to the cytoplasm of a cell.”

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.